Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Vipoma 1Somatostatinoma 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 6Sunitinib 3Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Injections 2recombinant interferon alpha 2b-like protein 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1fludarabine phosphate 1cabozantinib 1batifiban 1abemaciclib 1X-Rays 1Sorafenib 1Phantoms, Imaging 1PM 01183 1Oxaliplatin 1Leucovorin 1Interleukin-13 1Fluorouracil 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cryotherapy 1Biopsy 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Leucovorin × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡